Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Harvard Business School
Dow
Moodys
Baxter

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Litigation Details for Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Docket   Start Trial Date Filed 2016-06-29
Court District Court, D. Delaware Date Terminated 2018-08-21
Cause 35:271 Patent Infringement Assigned To Kent A. Jordan
Jury Demand None Referred To
Parties GENZYME CORPORATION; SANOFI-AVENTIS U.S. LLC; ZYDUS PHARMACEUTICALS (USA) INC.
Patents 6,987,102; 7,897,590
Attorneys Alison J. Baldwin; Chad A. Landmon; Dan Feng Mei; Daniel Gelwicks; David K. Ludwig; Dominick T. Gattuso; Edward M. Mathias; James L Lovsin; Jeffrey B. Bove; Jeremy E. Noe; Karen Riesenburger Poppel; Kurt W. Rohde; Nicole E Grimm; Paul H. Berghoff; Paula S. Fritsch
Firms Heyman Enerio Gattuso & Hirzel LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Genzyme Corporation v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2018-08-21 109 Judgment ofU.S. Patent No. 6,987,102 ("the '102 patent") and claims 8 and 19 ofU.S. Patent No., …claim 8 of the '1 02 patent and claims 8 and 19 of the '590 patent, to the extent that those…claim 8 of the '1 02 patent and claims 8 and 19 ofthe '590 patent, and the use, sale, or offer…claim 8 of the '1 02 patent and claims 8 and 19 of the '590 patent, and because those claims…, 7,897,590 ("the '590 patent") are invalid due to derivation (or anticipation), obviousness External link to document
2018-08-21 111 Patent/Trademark Report to Commissioner of Patents Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,897,590 B2 ;US 6,987,102 B2. (nmg)…2016 21 August 2018 1:16-cv-00540 830 Patent None District Court, D. Delaware External link to document
2016-06-29 4 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,897,590 B2; US 6,987,102 B2;. (sar…2016 21 August 2018 1:16-cv-00540 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Boehringer Ingelheim
Merck
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.